SaNOtize is a biotech company that utilizes a proprietary platform to deliver nitric oxide topically, harnessing its natural antimicrobial properties to treat upper respiratory and dermal infections. This technology provides a targeted approach to combatting pathogens, including viruses, without the use of traditional antibiotics.
Funding
$32.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Upper respiratory and dermal infections are often treated with traditional antibiotics, which can contribute to antibiotic resistance and disrupt the body's natural microbiome. Current topical treatments may lack targeted delivery and broad-spectrum antimicrobial activity.
Solution
SaNOtize has developed a platform for delivering nitric oxide (NO) topically to treat upper respiratory and dermal infections. This technology harnesses the natural antimicrobial properties of nitric oxide to combat pathogens, including viruses, without relying on traditional antibiotics. The platform provides a targeted approach to address infections.
Target Audience
The primary audience includes individuals seeking treatments for upper respiratory and dermal infections, as well as healthcare providers looking for alternative antimicrobial therapies.
Features
- Topical delivery of nitric oxide (NO)
- Broad-spectrum antimicrobial activity against viruses and other pathogens
- Targeted treatment of upper respiratory and dermal infections
- Potential to reduce reliance on traditional antibiotics